

# Australis Capital Inc

11:46 11 Dec 2019

## Australis Capital merging with Folium Biosciences to create vertically integrated producer of CBD

Australis Capital Inc (CSE:AUSA) (OTCMKTS:AUSAF) announced Wednesday it is merging with Folium Biosciences to create a vertically integrated producer of CBD.

Under the merger plan signed on December 10, Folium will become a wholly owned subsidiary of Australis -- which will be rebranded as Folium Biosciences and will carry on the current business of Folium.

"AUSA made a strategic investment in Folium almost a year ago after spending six months getting to know (Folium CEO Kashif Shan), his exceptional team, and their unparalleled proprietary ecosystem all supported by significant due diligence on the non-psychoactive cannabinoid space in the US and abroad," said Australis CEO Scott Dowty in a statement.

### READ: Australis Capital's Cocoon Technology partners with THRIVE Cannabis Marketplace to install kiosks across Nevada

"AUSA is uniquely positioned to add immediate and material value to Folium with a management team with combined decades of experience in public companies to guide Folium as the newly-legal CBD market in the US continues to grow," Dowty added.

Founded in 2014, Colorado Springs, Colorado-based Folium has grown into a substantial vertically integrated B2B producer, manufacturer, and distributor of broad-spectrum hemp-derived non-psychoactive cannabinoids in North America. Folium's proprietary processes and infrastructure deliver high-quality products to diverse industries across the US and to 27 countries.

Folium is on track to achieve in excess of 60% sales growth in 2019 and expects continued growth with a new purpose-built extraction facility, which is anticipated to come online in early 2020 and deliver approximately 10 times Folium's current extraction capacity.

Folium, privately held, has invested heavily in producing broad-spectrum hemp oil in its most natural form through an innovative extraction and purification process. Most importantly, Folium Bioscience has achieved this growth while being profitable from its first year of operation.

Additional information concerning Folium, including financial information and costs associated with the construction of Folium's new purpose-built extraction facility, will be contained in Australis' management information circular to be prepared in connection with a meeting of shareholders.

"Folium is truly unique in that our exponential growth has been all organic and funded through our sales which has enabled us to demonstrate a track record of consistent profitability," said Folium CEO Kashif Shan.

"Now, with access to the public markets and the strategic addition of key seasoned management personnel experienced in operating a public company, we are positioned to navigate to the next level of success in concert with

**Price:** 0.265

**Market Cap:** \$44.37 m

### 1 Year Share Price Graph



February 2019 July 2019 February 2020

### Share Information

**Code:** AUSA

**Listing:** CSE

**52 week High Low**  
1.4 0.235

**Sector:** Cannabis

**Website:** www.ausacap.com

### Company Synopsis:

A spin-out of Aurora Cannabis (NYSE: ACB&nbsp;TSX: ACB) in September 2018, Australis identifies and invests in the cannabis industry predominantly in the United States, a highly-regulated, fragmented, rapidly-expanding and evolving industry.

action@proactiveinvestors.com

the existing leadership team here at Folium."

Folium's existing management team has over 100 years of collective experience in consumer products, food, and pharmaceuticals, with an overall team of 242 employees. With this experience, Folium drives innovation in cannabinoid research, development, and extraction. Folium's goal is to exceed the standards for analytical test methodology with a full suite of testing at every step of the process.

### **Australis shares halted**

Currently, Australis' shares have been halted at the Canadian Securities Exchange until the filing of the management information circular and the completion of all filings with the exchange.

Once the transaction is completed, members of Folium will exchange their units for common shares of Australis such that current shareholders will hold about 11% of Australis shares and current members of Folium will hold about 89% shares, resulting in a reverse takeover of Australis, which will re-incorporate under the laws of the State of Delaware.

A special meeting of Australis shareholders, which has yet to be scheduled, is needed to approve the merger, reverse stock split, and Delaware re-incorporation.

Also in order to avoid being classified as an investment company under the US Investment Company Act of 1940, Australis said it intends to divest certain investment assets prior to the completion of the merger.

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### **No investment advice**

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Australis Capital Inc named herein, including the promotion by the Company of Australis Capital Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five

Thousand

dollars

(\$25,000).